Monopar initiates Phase 1a trial of MNPR-101-Lu radiopharmaceutical therapy in advanced cancers

Monopar Therapeutics

Phase 1a open-label dose-escalation study of MNPR-101-Lu in solid tumors now recruiting.
First site activated: Melbourne Theranostic Innovation Centre in Australia.
Trial open only to patients in ongoing MNPR-101-Zr Phase 1 imaging/dosimetry trial.
MNPR-101 targets uPAR, expressed in pancreatic, breast, colorectal, ovarian, and bladder cancers.
CEO says trial launched months ahead of original schedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.